Lumos Diagnostics (ASX: LDX), known for its rapid point-of-care (POC) diagnostics tests, has expanded its partnership with Henry Schein Medical to add Belgium to its distribution list. This agreement makes FebriDx, a rapid test designed to differentiate viral from bacterial infections, accessible to Belgian healthcare professionals. FebriDx delivers results in 10 minutes from a fingerstick
Read More
A recent report revealed that, in the US, the rate of babies being born prematurely has been rising. Between 2014 and 2022, premature births grew 12% to 8.7%. This paints a concerning picture for mothers and infants who face great risk. To address this, point-of-care diagnostic technologies Lumos Diagnostics (ASX: LDX) has been working on
Read More
Diagnostic tech company Lumos Diagnostics (ASX: LDX) has received the green card from the US Food and Drug Administration (FDA) to market its FebriDx rapid, point-of-care test in the United States. This regulatory clearance permits the marketing of FebriDx in the US as an aid for healthcare professionals in diagnosing bacterial acute respiratory infections and
Read More
One of the punching bags of the ASX, Lumos Diagnostics (ASX: LDX), which develops diagnostics for healthcare professionals to more accurately diagnose and manage medical conditions, has announced the closure of its Sarasota manufacturing facility in Florida as they shift operations across the country to Carlsbad, California. The decision to close one of its sites
Read More
Cash, it’s the lifeblood of any business and while their specialty in early stage disease diagnosis, Lumos Diagnostics (ASX: LDX) has finally applied the same thinking to their business having identified unsalvageable cash burn, prompting the closure of their Florida manufacturing facility. Although the US healthcare market is the world’s most lucrative, Lumos will cease
Read More
While small cap shareholders have become accustomed to major share price gains once a medtech or biotech receives FDA approval to commercialise their products, it’s not all sunshine and rainbows on the FDA horizon as Lumos Diagnostics (ASX: LDX) has found, following the rejection of their FebriDx test kits. As a rapid diagnostic test that
Read More